top of page
  • Foto del escritorThe Corporate Reviews

Ismail Shehada

CEO, Tabuk Pharmaceuticals


Describe Tabuk Pharmaceuticals

Since Tabuk Pharmaceuticals inception in 1994 in Riyadh has solidified its position as the premier/largest privately-owned pharmaceutical enterprise in Saudi Arabia. Today, our influence spans across the Middle East and Africa (MEA) region, marking us as a leader in pharmaceutical excellence.

From our humble beginnings as a family business, we have transformed into Saudi Arabia's foremost private pharmaceutical institution. This growth mirrors our unwavering dedication to health and well-being.

Driven by our commitment to patients, we are dedicated to offering high-quality medications. Our expansive portfolio includes the development, production, and distribution of a myriad of branded pharmaceutical items. We take pride in manufacturing for numerous international and regional companies within our cutting-edge facilities in Saudi Arabia. Partnering with us extends beyond business; we offer licensing to regional allies, empowering them to produce and market our innovative solutions.

At the heart of Tabuk is our state-of-the-art Research and Development (R&D) facility. Our team of experts is dedicated to pioneering solutions and developing medicines for a wide range of therapeutic areas, including cardiovascular, respiratory, central nervous system, musculoskeletal, infectious diseases, and GI & diabetes.

Our team of over 2,400 dedicated professionals operate from four advanced manufacturing sites: Tabuk and Dammam in Saudi Arabia, as well as strategic positions in Sudan and Algeria. These sites are responsible for producing an impressive 2 billion base units each year, underscoring our commitment to health across 17 MENA countries.

Aligned with Saudi Arabia's Vision 2030, we're proactive in bolstering the nation's healthcare and pharmaceutical sectors. As trailblazers, our focus is on enriching partnerships with entities, and patients alike. Together, we're scripting a transformative narrative for regional therapeutic and healthcare systems.

What are the main medical solutions in which Tabuk Pharmaceuticals is currently working?

Developing and marketing a wide range of branded generic and under-licensed products in various dosage forms serving a wide range of therapeutic areas such as Cardiovascular, Central nervous, Musculoskeletal, Infectious, Respiratory, GI and diabetes. We manufacture high-quality products at sterile and non-sterile cephalosporin and non-cephalosporin plants. Distributing pharmaceutical products in 17 countries in the Middle East and Africa.

How are the Middle East and North Africa making an impact in the medical field?

The Middle East and North Africa (MENA) region is making a significant impact in the medical field through various initiatives and advancements. As Tabuk Pharmaceuticals, we are proud to contribute to this progress. Here are a few key ways MENA is making an impact:

  1. Access to Healthcare: The MENA region has been working diligently to improve access to quality healthcare for its growing population. Governments and healthcare providers are investing in infrastructure, expanding medical services, and implementing health insurance schemes to ensure more people have access to essential healthcare services.

  2. Research and Development: The region is witnessing a surge in research and development activities in the medical field. Academic institutions, pharmaceutical companies, and research centers are collaborating to advance medical knowledge, develop innovative treatments, and address prevalent diseases and healthcare challenges specific to the region.

  3. Pharmaceutical Manufacturing: The MENA region, including Tabuk Pharmaceuticals, plays a crucial role in pharmaceutical manufacturing. The region has well-established manufacturing facilities adhering to international standards, producing a wide range of pharmaceutical products. This local production not only ensures a secure supply of medicines but also creates employment opportunities and contributes to the region's economic growth.

  4. Medical Tourism: MENA countries have become popular destinations for medical tourism. With state-of-the-art healthcare facilities, highly skilled healthcare professionals, and competitive pricing, patients from around the world seek medical treatments in the region. This boosts the local economy and promotes cross-cultural exchange in the medical field.

  5. Digital Health Innovation: The MENA region is embracing digital health technologies to transform healthcare delivery. Telemedicine, digital health platforms, and health apps are improving access to healthcare services, enabling remote consultations, and facilitating better patient engagement. These innovations are enhancing the efficiency and effectiveness of healthcare delivery in the region.

The Middle East and North Africa are making a profound impact in the medical field through improved access to healthcare, advancements in research and development, robust pharmaceutical manufacturing, medical tourism, and digital health innovations. These efforts are collectively contributing to the growth and development of the region's healthcare sector and ultimately improving the well-being of its population.

Regarding that, what is the approach of Tabuk Pharmaceuticals in making new partners in the rest of the world? What does the company gain from these partnerships?

At Tabuk Pharmaceuticals, we value strategic partnerships as a means to expand our global presence and enhance our capabilities. Our approach to making new partners in the rest of the world is guided by a few key principles:

Collaborative Relationships: We seek partnerships based on mutual trust, shared values, and a common vision. By fostering collaborative relationships, we aim to leverage the strengths and expertise of our partners to drive innovation, explore new markets, and deliver high-quality healthcare solutions.

Market Expansion: Partnering with reputable companies worldwide allows us to extend our reach and enter new markets. Through these collaborations, we can navigate regulatory requirements, establish local presence, and leverage the market knowledge and distribution networks of our partners to effectively introduce our products to diverse regions.

Product Portfolio Enhancement: Partnering with renowned organizations enables us to complement our existing product portfolio with novel offerings. By accessing cutting-edge technologies, innovative therapies, and under-licensed products, we can provide a wider range of treatment options to healthcare professionals and patients, strengthening our competitive position in the global pharmaceutical landscape.

Knowledge Exchange and Capacity Building: Collaborating with international partners’ fosters knowledge exchange and facilitates the transfer of best practices. By learning from each other's experiences, expertise, and approaches to healthcare, we can enhance our capabilities, improve processes, and accelerate our growth trajectory.

Long-Term Sustainability: Our partnerships are built with a long-term perspective in mind. We aim to establish stable and sustainable relationships that go beyond immediate gains. By nurturing enduring partnerships, we create a foundation for ongoing collaboration, joint research, and shared success, ultimately benefiting patients and contributing to the advancement of global healthcare.

Through these partnerships, Tabuk Pharmaceuticals gains access to new markets, expands its product portfolio, enhances its capabilities, and fosters innovation. Additionally, these collaborations allow us to extend our global reach, establish a strong international presence, and contribute to the improvement of healthcare on a global scale.

What have been the biggest challenges for the company and pharmaceutical companies since Covid started?

Since the onset of the COVID-19 pandemic, the total pharmaceutical industry, and many pharmaceutical companies, has faced several significant challenges. Some of the most prominent challenges include:

Supply Chain Disruptions: The pandemic has disrupted global supply chains, affecting the availability and distribution of raw materials, active pharmaceutical ingredients (APIs), and finished products. Lockdown measures, travel restrictions, and increased demand for certain medications have strained supply chains, leading to shortages and delays in manufacturing and distribution.

Research and Development Setbacks: The focus of research and development (R&D) efforts across the pharmaceutical industry shifted towards COVID-19 treatments and vaccines. This diverted resources and attention away from other therapeutic areas, causing delays in the development of new drugs and treatments for various diseases.

Clinical Trial Disruptions: COVID-19 has significantly impacted clinical trials worldwide. Lockdown measures, reduced patient access to healthcare facilities, and prioritization of COVID-19-related trials have led to disruptions and delays in ongoing clinical trials. This has affected the timely availability of new treatments and therapies.

Changes in Healthcare Delivery: The pandemic has brought about fundamental changes in healthcare delivery, including a shift towards telemedicine and virtual consultations. Pharmaceutical companies have had to adapt their marketing and sales strategies to this new landscape, finding innovative ways to engage with healthcare professionals remotely.

Vaccine Distribution and Vaccine Hesitancy: The global rollout of COVID-19 vaccines has presented logistical challenges in terms of manufacturing, distribution, and equitable access. Additionally, vaccine hesitancy and misinformation have posed challenges in achieving widespread vaccination coverage and controlling the spread of the virus.

Despite these challenges, the pharmaceutical industry has demonstrated resilience and adaptability, working tirelessly to address the evolving needs of patients and society during this unprecedented time. Collaboration, innovation, and a shared commitment to public health have been crucial in navigating the challenges posed by the pandemic.

How are new technologies changing the way that pharmaceutical companies work and develop their products?

New technologies are revolutionizing the way pharmaceutical companies work and develop their products in several key ways:

Drug Discovery and Development: Advanced technologies such as artificial intelligence (AI), machine learning, and data analytics are transforming the drug discovery process. These tools enable companies to analyze large datasets, identify drug targets, and predict the efficacy and safety of potential compounds. This accelerates the identification and optimization of promising drug candidates, reducing time and costs associated with traditional trial-and-error approaches.

Precision Medicine: Technologies like genomics, proteomics, and biomarker analysis enable personalized medicine approaches. Pharmaceutical companies can now identify specific patient populations that are more likely to respond positively to their therapies. This leads to better targeting of treatments, improved patient outcomes, and reduction in adverse events.

Manufacturing and Quality Control: Automation, robotics, and process optimization technologies are enhancing pharmaceutical manufacturing. These advancements improve efficiency, reduce errors, and ensure consistent quality across production lines. Real-time monitoring and data analytics enable proactive identification of potential issues, facilitating timely intervention and maintaining high manufacturing standards.

Digital Health Solutions: Pharmaceutical companies are increasingly integrating digital health solutions into their products. This includes the use of wearable devices, remote monitoring tools, and mobile applications to track patient health, collect real-time data, and enhance medication adherence. These technologies enable better patient engagement, improved treatment outcomes, and the generation of valuable real-world evidence.

Regulatory Compliance and Safety: Technologies such as blockchain and secure data systems are enhancing transparency, traceability, and security in the pharmaceutical supply chain. These solutions help ensure regulatory compliance, prevent counterfeit drugs, and streamline pharmacovigilance efforts to monitor and report adverse events more effectively.

Patient Engagement and Education: Digital technologies provide platforms for pharmaceutical companies to engage with patients directly where appropriate, providing educational resources, disease management tools, and support networks. Social media, online communities, and health apps facilitate communication, empower patients, and enhance medication adherence.

Overall, new technologies are empowering pharmaceutical companies to work more efficiently, accelerate drug development, improve manufacturing processes, tailor treatments to individual patients, and enhance patient engagement. Embracing these technological advancements is crucial for staying competitive, driving innovation, and ultimately improving patient outcomes in the rapidly evolving healthcare landscape.

Finally, how do you expect the company to grow in the next few years?


Expansion into New Markets: We often seek to expand our presence in new geographic regions or countries to tap into emerging markets or gain access to a larger customer base. This expansion may involve establishing local manufacturing facilities, entering into strategic partnerships with a strong presence in the target markets.

Portfolio Diversification: A company's growth can be fueled by diversifying its product portfolio. This may involve developing new drugs or therapeutic areas, expanding into different dosage forms or delivery mechanisms, or acquiring licenses for innovative products. Diversification helps companies address a wider range of patient needs and capture market opportunities.

Research and Development: Continued investment in research and development is vital for any pharmaceutical company to develop innovative treatments, improve existing products, and address unmet medical needs. Investing in cutting-edge technologies and collaborations with academic institutions or research organizations can drive scientific advancements and strengthen the company's competitive position.

Strategic Partnerships and Collaborations: Collaborations with other pharmaceutical companies, research institutions, or technology firms can provide access to complementary expertise, resources, and technologies. Joint ventures, licensing agreements, or research collaborations can expedite product development, enhance market reach, and foster innovation.

Emerging Therapeutic Areas: Keeping up with advancements in science and technology and identifying emerging therapeutic areas with high growth potential is crucial. Pharmaceutical companies that are at the forefront of developments in areas such as gene therapy, precision medicine, or digital health solutions may have a competitive advantage and strong growth prospects.

Market Trends and Global Healthcare Landscape: Monitoring market trends, changes in healthcare policies, and evolving patient needs is essential for adapting strategies and identifying growth opportunities. Factors such as an aging population, increasing prevalence of chronic diseases, or shifts towards value-based healthcare models can shape the company's growth trajectory.

It is important to note that the actual growth of a pharmaceutical company depends on various internal and external factors, market dynamics, regulatory landscape, and competitive environment. Companies need to assess these factors and develop robust strategies to position themselves for growth in the coming years.


Commenting has been turned off.
bottom of page